United Therapeutics Corporation $UTHR Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 21.7% in the third quarter, Holdings Channel reports. The firm owned 27,500 shares of the biotechnology company’s stock after selling 7,600 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in United Therapeutics were worth $11,528,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Eagle Global Advisors LLC purchased a new stake in United Therapeutics during the third quarter worth approximately $210,000. Concurrent Investment Advisors LLC raised its stake in shares of United Therapeutics by 9.5% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 957 shares of the biotechnology company’s stock valued at $401,000 after acquiring an additional 83 shares during the period. Harbor Investment Advisory LLC lifted its holdings in shares of United Therapeutics by 148.6% during the 3rd quarter. Harbor Investment Advisory LLC now owns 619 shares of the biotechnology company’s stock valued at $259,000 after acquiring an additional 370 shares in the last quarter. Marquette Asset Management LLC boosted its position in United Therapeutics by 102.3% during the 3rd quarter. Marquette Asset Management LLC now owns 809 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 409 shares during the period. Finally, Cardinal Capital Management boosted its position in United Therapeutics by 1.8% during the 3rd quarter. Cardinal Capital Management now owns 12,084 shares of the biotechnology company’s stock worth $5,066,000 after purchasing an additional 208 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $427.41, for a total value of $9,616,725.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 597,814 shares of company stock worth $280,924,148. 10.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on UTHR shares. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. Wells Fargo & Company raised their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Stock Down 1.5%

UTHR stock opened at $464.93 on Friday. The stock’s 50 day moving average is $486.85 and its two-hundred day moving average is $408.02. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The company has a market capitalization of $20.02 billion, a PE ratio of 17.62, a P/E/G ratio of 2.45 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $6.39 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.